statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

Enveric Biosciences (NASDAQ: ENVB) (Enveric), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announced...

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Enveric Biosciences (NASDAQ: ENVB) (Enveric), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, and Aries Science...

New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies

Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological disorders, including depression and anxiety.
read more...

Enveric Biosciences Announces Patent Granted for Drug Candidate

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today...

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...

Enveric Biosciences to Participate in BIO International Convention 2024

'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024.'We believe the first quarter of 2024 was a highly productive period for Enveric as the...

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Enveric Biosciences, Inc (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and...

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company was founded on February 28, 1994 and is headquartered in Naples, FL.

Volume	312,509.00
52-Wk High	$3.90
52-Wk Low	$0.41

Current Price	$0.4703
Prev Close	$0.471
Open	$0.485
Dividend Yield	0.00%
50-Day Moving Average	$0.6526
Beta	1.81
Avg. Volume	93,039.26
PE Ratio	-0.07

52-Week High	$3.90
52-Week Low	$0.41
Market Capitalization	$3.74M
EPS	-$6.42
Price to Book	0.53
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	0.17

ENVB Enveric Biosciences Inc

About

Feed

News

Sentiment

Fundamentals